Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging

Silva, Leanne De; Fu, Ju-Yen; Htar, Thet Thet; Kamal, Wan Hamirul Bahrin Wan; Kasbollah, Azahari; Muniyandy, Saravanan; Chuah, Lay Hong

doi:10.3389/fphar.2021.778396

Cited by 9 publications

(5 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to set the critical range for zeta potential (mV), biologically acceptable range kept as -10-10 mV. (43) Based on all preliminary set-up target ranges in size (nm), PDI, and zeta potential (mV), all obtained data were considered to be within the critical range. The predicted formulations were also compared with experimentally obtained data by applying the similarity test (F-score: 0.83).…”

Section: Physicochemical Characterizationmentioning

confidence: 99%

Optimizing Niosome Formulations for Enhanced Cellular Applications: A Comparative Case Study with L-α-lecithin Liposomes

Cakir,

Ozturk,

Kara

et al. 2023

Preprint

View full text Add to dashboard Cite

Niosomes, emerging as nonionic surfactant-derived amphiphilic nanoparticles, hold substantial promise in the realm of biomedical research. This study addresses the need for a comprehensive exploration of niosome production optimization for biological applications, while also establishing meaningful comparisons with the well-established liposomal counterparts. Beyond conventional stability assessments, our motivation centers on discerning not only critical niosome process parameters but also on devising cost-effective, scalable alternatives to liposomes through comparative studies of liposomes and niosomes, rather than solely emphasizing niosomal stability advantages.The primary objective of this study is to formulate and characterize a diverse array of niosomal nanoparticles, with a prime focus on their process-related parameters, physicochemical characteristics, cellular uptake, and toxicity performances. To establish the niosomes as their research twins of liposomes, the gap in the research field is picked as the starting point. The study is designed with stringent criteria based on the limitations of vasculature-tissue barriers. The proposed encompassing size (100-200 nm), polydispersity below 0.5, and zeta potential within the range of -10 to 10 mV are set for this purpose. These criteria serve as the initial screening parameters, streamlining the selection of niosome formulations with the potential to overcome the barriers. Through meticulous physicochemical characterization, we synthesized 10 optimized formulations aligned with the targeted size, polydispersity, and zeta potential ranges. In this physicochemical critical process parameter screening, short and long-term stability, shelf-life aggregation profiles, and the reproducibility of formulations were also assessed to confidently report the potential niosomal formulations for further drug delivery purposes. The statistical evaluations and analytical screening of process parameters obtained from the DoE interface indicated that most formulations maintain their critical criteria for at least 21 days, with three formulations remaining stable for 35 days. Reproducibility tests further validate the consistency of eight out of ten formulations regarding size, polydispersity, and surface charge. The F-score confirms high similarity between predicted and observed physicochemical properties (F-score = 0.83) for reproducibility tests.Concurrently, we explore the pivotal process parameters governing niosome preparation and their consequential impact on physicochemical attributes. Further, physiochemically selected niosomal carriers are simultaneously exposed to cellular applications with L-α-lecithin liposomes including cellular toxicity and cellular uptake. In cellular toxicity, the selected niosomes from physicochemical screening were exposed to two different cancerous cell lines belonging to glioblastoma multiform (U-87 MG) and lymphoblast-like cell line (NFS-60). The cellular uptake profiles in U-87 MG and simultaneous comparison with liposomes revealed non-toxicity across all formulations and promising cellular uptake performance in four formulations, either similar to or better than liposomes.Overall, this study holds potential implications of niosomes for advancing reliable drug delivery strategies, enhancing treatment efficacy, and ensuring safety in various therapeutic applications. Besides, demonstrating the scientific records of physiochemically controlled niosomes’ similarity to a type of liposomes in cellular interactions and scalable production will ultimately expand their applications in the field of biomedical research.

show abstract

Section: Physicochemical Characterizationmentioning

confidence: 99%

Optimizing Niosome Formulations for Enhanced Cellular Applications: A Comparative Case Study with L-α-lecithin Liposomes

Cakir,

Ozturk,

Kara

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…De Silva et al successfully demonstrated the manufacture of prototypical 99m Tc conjugated niosomes through a simple and fast one-step method [ 133 ]. Their work indicated the feasibility of the developed radio-niosomes for in vivo administration, resulting in high tumour to muscle uptake.…”

Section: Specialised Niosomesmentioning

confidence: 99%

Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications

Witika

Bassey

Demana

et al. 2022

IJMS

View full text Add to dashboard Cite

Development of nanomaterials for drug delivery has received considerable attention due to their potential for achieving on-target delivery to the diseased area while the surrounding healthy tissue is spared. Safe and efficiently delivered payloads have always been a challenge in pharmaceutics. Niosomes are self-assembled vesicular nanocarriers formed by hydration of a non-ionic surfactant, cholesterol or other molecules that combine to form a versatile drug delivery system with a variety of applications ranging from topical delivery to targeted delivery. Niosomes have advantages similar to those of liposomes with regards to their ability to incorporate both hydrophilic and hydrophobic payloads. Moreover, niosomes have simple manufacturing methods, low production cost and exhibit extended stability, consequently overcoming the major drawbacks associated with liposomes. This review provides a comprehensive summary of niosomal research to date, including the types of niosomes and critical material attributes (CMA) and critical process parameters (CPP) of niosomes and their effects on the critical quality attributes (CQA) of the technology. Furthermore, physical characterisation techniques of niosomes are provided. The review then highlights recent applications of specialised niosomes in drug delivery. Finally, limitations and prospects for this technology are discussed.

show abstract

“…15 Although niosomes are chemically similar to phospholipid vesicles (liposomes), they have a number of important advantages over them, including affordability, ease of storage, and increased stability (longer shelf life). 16,17 Several radiochemical processes (direct, chelator-mediated, and encapsulation) can be used to radioactively label nanoparticulate drug delivery systems with a specific radionuclide. One approach is the encapsulation of the radionuclide on the nanocarrier during synthesis.…”

Section: Introductionmentioning

confidence: 99%

“…They have received a great deal of interest as effective nanocarriers to deliver anticancer agents, chemicals, vaccines, proteins, and genes because of their excellent drug delivery capacity, including controlled release, targeted delivery, fewer adverse effects, enhanced bioavailability, and wide formulation variability . Although niosomes are chemically similar to phospholipid vesicles (liposomes), they have a number of important advantages over them, including affordability, ease of storage, and increased stability (longer shelf life). , …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

et al. 2023

View full text Add to dashboard Cite

The aim of this research was to develop technetium-99m ([99mTc]Tc)-radiolabeled niosomes and evaluate the cancer cell incorporation capacity of radiolabeled niosomes. For this purpose, niosome formulations were developed by film hydration method, and prepared niosomes were characterized to particle size, polydispersity index (PdI), ζ-potential value, and image profile. Then, niosomes were radiolabeled with [99mTc]Tc using stannous salts (chloride) as a reducing agent. The radiochemical purity (RP) and stability in different mediums of the niosomes were assessed by ascending radioactive thin-layer chromatography (RTLC) and radioactive ultrahigh-performance liquid chromatography (R-UPLC) methods. Also, the partition coefficient value of radiolabeled niosomes was determined. The cell incorporation of [99mTc]Tc-labeled niosome formulations, as well as reduced/hydrolyzed (R/H)-[99mTc]NaTcO4 in the HT-29 (human colorectal adenocarcinoma) cells, was then assessed. According to the obtained results, the spherical niosomes had a particle size of 130.5 ± 1.364 nm, a PdI value of 0.250 ± 0.023, and a negative charge of −35.4 ± 1.06 mV. The niosome formulations were effectively radiolabeled with [99mTc]Tc using 500 μg mL–1 stannous chloride for 15 min, and RP was found to be over 95%. [99mTc]Tc-niosomes showed good in vitro stability in every system for up to 6 h. The log P value of radiolabeled niosomes was found as −0.66 ± 0.02. Compared to R/H-[99mTc]NaTcO4 (34.18 ± 1.56%), the incorporation percentages of [99mTc]Tc-niosomes (88.45 ± 2.54%) were shown to be higher in cancer cells. In conclusion, the newly developed [99mTc]Tc-niosomes showed good prototype for potential use in nuclear medicine imaging in the near future. However, further investigations, such as drug encapsulation and biodistribution studies, should be performed, and our studies are continuing.

show abstract

Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging

Cited by 9 publications

References 66 publications

Optimizing Niosome Formulations for Enhanced Cellular Applications: A Comparative Case Study with L-α-lecithin Liposomes

Optimizing Niosome Formulations for Enhanced Cellular Applications: A Comparative Case Study with L-α-lecithin Liposomes

Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

Contact Info

Product

Resources

About

Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging

Cited by 9 publications

References 66 publications

Optimizing Niosome Formulations for Enhanced Cellular Applications: A Comparative Case Study with L-α-lecithin Liposomes

Optimizing Niosome Formulations for Enhanced Cellular Applications: A Comparative Case Study with L-α-lecithin Liposomes

Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications

[99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

Contact Info

Product

Resources

About

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation